vs
Brookfield Infrastructure Corp（BIPC）与UNITED THERAPEUTICS Corp（UTHR）财务数据对比。点击上方公司名可切换其他公司
Brookfield Infrastructure Corp的季度营收约是UNITED THERAPEUTICS Corp的1.1倍（$866.0M vs $790.2M），UNITED THERAPEUTICS Corp净利率更高（46.1% vs -35.7%，领先81.8%），UNITED THERAPEUTICS Corp同比增速更快（7.4% vs -4.6%）
布鲁克菲尔德基础设施合伙公司是一家公开上市的有限合伙企业，总部位于加拿大多伦多，核心业务为在全球范围内开展基础设施资产的收购、运营与管理，在全球基础设施投资领域拥有深厚的行业积累与较强的市场影响力。
United Therapeutics是美国生物技术企业，专注开发包含异种移植在内的器官移植相关药物与技术，多款产品布局肺部疾病及器官制造赛道，双总部位于马里兰州银泉与北卡罗来纳州三角研究园，在美加多地设有研发及运营分支机构。
BIPC vs UTHR — 直观对比
营收规模更大
BIPC
是对方的1.1倍
$790.2M
营收增速更快
UTHR
高出12.0%
-4.6%
净利率更高
UTHR
高出81.8%
-35.7%
损益表 — Q2 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $866.0M | $790.2M |
| 净利润 | $-309.0M | $364.3M |
| 毛利率 | 65.0% | 86.9% |
| 营业利润率 | 62.7% | 45.1% |
| 净利率 | -35.7% | 46.1% |
| 营收同比 | -4.6% | 7.4% |
| 净利润同比 | -148.1% | 20.9% |
| 每股收益（稀释后） | — | $7.66 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BIPCUTHR
| Q4 25 | — | $790.2M | ||
| Q3 25 | — | $799.5M | ||
| Q2 25 | $866.0M | $798.6M | ||
| Q1 25 | — | $794.4M | ||
| Q4 24 | — | $735.9M | ||
| Q3 24 | — | $748.9M | ||
| Q2 24 | $908.0M | $714.9M | ||
| Q1 24 | — | $677.7M |
净利润BIPCUTHR
| Q4 25 | — | $364.3M | ||
| Q3 25 | — | $338.7M | ||
| Q2 25 | $-309.0M | $309.5M | ||
| Q1 25 | — | $322.2M | ||
| Q4 24 | — | $301.3M | ||
| Q3 24 | — | $309.1M | ||
| Q2 24 | $643.0M | $278.1M | ||
| Q1 24 | — | $306.6M |
毛利率BIPCUTHR
| Q4 25 | — | 86.9% | ||
| Q3 25 | — | 87.4% | ||
| Q2 25 | 65.0% | 89.0% | ||
| Q1 25 | — | 88.4% | ||
| Q4 24 | — | 89.7% | ||
| Q3 24 | — | 88.9% | ||
| Q2 24 | 63.8% | 89.1% | ||
| Q1 24 | — | 89.2% |
营业利润率BIPCUTHR
| Q4 25 | — | 45.1% | ||
| Q3 25 | — | 48.6% | ||
| Q2 25 | 62.7% | 45.6% | ||
| Q1 25 | — | 48.2% | ||
| Q4 24 | — | 48.6% | ||
| Q3 24 | — | 45.8% | ||
| Q2 24 | 61.9% | 44.7% | ||
| Q1 24 | — | 52.6% |
净利率BIPCUTHR
| Q4 25 | — | 46.1% | ||
| Q3 25 | — | 42.4% | ||
| Q2 25 | -35.7% | 38.8% | ||
| Q1 25 | — | 40.6% | ||
| Q4 24 | — | 40.9% | ||
| Q3 24 | — | 41.3% | ||
| Q2 24 | 70.8% | 38.9% | ||
| Q1 24 | — | 45.2% |
每股收益（稀释后）BIPCUTHR
| Q4 25 | — | $7.66 | ||
| Q3 25 | — | $7.16 | ||
| Q2 25 | — | $6.41 | ||
| Q1 25 | — | $6.63 | ||
| Q4 24 | — | $6.23 | ||
| Q3 24 | — | $6.39 | ||
| Q2 24 | — | $5.85 | ||
| Q1 24 | — | $6.17 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.2B | $2.9B |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $2.2B | $7.1B |
| 总资产 | $23.9B | $7.9B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资BIPCUTHR
| Q4 25 | — | $2.9B | ||
| Q3 25 | — | $2.8B | ||
| Q2 25 | $1.2B | $3.0B | ||
| Q1 25 | — | $3.3B | ||
| Q4 24 | — | $3.3B | ||
| Q3 24 | — | $3.3B | ||
| Q2 24 | $466.0M | $3.0B | ||
| Q1 24 | — | $2.7B |
股东权益BIPCUTHR
| Q4 25 | — | $7.1B | ||
| Q3 25 | — | $6.6B | ||
| Q2 25 | $2.2B | $7.2B | ||
| Q1 25 | — | $6.8B | ||
| Q4 24 | — | $6.4B | ||
| Q3 24 | — | $6.1B | ||
| Q2 24 | $3.5B | $5.7B | ||
| Q1 24 | — | $5.3B |
总资产BIPCUTHR
| Q4 25 | — | $7.9B | ||
| Q3 25 | — | $7.4B | ||
| Q2 25 | $23.9B | $7.9B | ||
| Q1 25 | — | $7.7B | ||
| Q4 24 | — | $7.4B | ||
| Q3 24 | — | $7.1B | ||
| Q2 24 | $23.7B | $6.7B | ||
| Q1 24 | — | $6.5B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $478.0M | $346.2M |
| 自由现金流经营现金流 - 资本支出 | — | $173.3M |
| 自由现金流率自由现金流/营收 | — | 21.9% |
| 资本支出强度资本支出/营收 | — | 21.9% |
| 现金转化率经营现金流/净利润 | — | 0.95× |
| 过去12个月自由现金流最近4个季度 | — | $1.0B |
8季度趋势，按日历期对齐
经营现金流BIPCUTHR
| Q4 25 | — | $346.2M | ||
| Q3 25 | — | $562.1M | ||
| Q2 25 | $478.0M | $191.7M | ||
| Q1 25 | — | $461.2M | ||
| Q4 24 | — | $341.2M | ||
| Q3 24 | — | $377.2M | ||
| Q2 24 | $511.0M | $232.2M | ||
| Q1 24 | — | $376.5M |
自由现金流BIPCUTHR
| Q4 25 | — | $173.3M | ||
| Q3 25 | — | $351.6M | ||
| Q2 25 | — | $129.5M | ||
| Q1 25 | — | $386.3M | ||
| Q4 24 | — | $254.5M | ||
| Q3 24 | — | $300.7M | ||
| Q2 24 | — | $187.1M | ||
| Q1 24 | — | $338.3M |
自由现金流率BIPCUTHR
| Q4 25 | — | 21.9% | ||
| Q3 25 | — | 44.0% | ||
| Q2 25 | — | 16.2% | ||
| Q1 25 | — | 48.6% | ||
| Q4 24 | — | 34.6% | ||
| Q3 24 | — | 40.2% | ||
| Q2 24 | — | 26.2% | ||
| Q1 24 | — | 49.9% |
资本支出强度BIPCUTHR
| Q4 25 | — | 21.9% | ||
| Q3 25 | — | 26.3% | ||
| Q2 25 | — | 7.8% | ||
| Q1 25 | — | 9.4% | ||
| Q4 24 | — | 11.8% | ||
| Q3 24 | — | 10.2% | ||
| Q2 24 | — | 6.3% | ||
| Q1 24 | — | 5.6% |
现金转化率BIPCUTHR
| Q4 25 | — | 0.95× | ||
| Q3 25 | — | 1.66× | ||
| Q2 25 | — | 0.62× | ||
| Q1 25 | — | 1.43× | ||
| Q4 24 | — | 1.13× | ||
| Q3 24 | — | 1.22× | ||
| Q2 24 | 0.79× | 0.83× | ||
| Q1 24 | — | 1.23× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BIPC
暂无分部数据
UTHR
| Tyvaso DPI | $338.6M | 43% |
| Remodulin | $128.0M | 16% |
| Nebulized Tyvaso | $125.7M | 16% |
| Orenitram | $121.2M | 15% |
| Unituxin | $62.3M | 8% |
| Adcirca | $7.8M | 1% |
| Other | $6.6M | 1% |
